Back to Research Hub
AnaptysBio, Inc.
ANAB
$51.63+0.27 (+0.53%)
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory…
StreetsValue research for AnaptysBio, Inc. (ANAB)
Members get the full report for AnaptysBio, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.